> Unfortunately these bozos should have been raising money and even diluting after the SNY partnership deal, but missed the window.
You're exactly right about that. The most important factor looking at any company is not whether they have an FDA approved drug, it's their balance sheet.
I put is squarely on Hakeen, though Al did let him run the show so he gets the indirect blame.
Would love to see Al put $50M or so in, but do not really expect it.
The clamp study just establishes the time model for a dose of Alfrezza, and how that compares to the same for other rapid acting insulins. This should have been done earlier, because it helps docs and patients understand how best to dose it.
International is far far away. The insurance issues in the EU are far worse than here.
I still think best is to divide the company.
Sell mfg to SNY and split off the Afrezza revenue stream to a stand alone company with near zero overhead.
What would be left is a dev stage biotech with Technosphere.
Shareholders get shares in both the "Afrezza" and "Technosphere" companies.
News 
Market Data 
Discover 
